VentiRx Pharmaceuticals

Developing new immunotherapies to advance the cancer treatment paradigm

VentiRx is one of the leading companies developing therapies to activate the immune system to address solid tumors. The company's lead product, motolimod, is a selective agonist of TLR-8 and stimulates myeloid-derived dendritic cells to produce and release inflammatory mediators to activate an immune response. VentiRx has entered into a worldwide strategic collaboration with Celgene for motolimod and is in clinical studies to treat ovarian and head & neck cancer.

Acquired by Celgene in 2017
Year of Investment
Life Sciences
Seattle, Washington